The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage. This abnormal wound-healing response distorts the liver's structure, ...

Health-care companies fell amid concerns about increased regulation and upheaval in the sector. UnitedHealth Group continued its retreat after the abrupt departure of its chief executive. Danish ...

Here are the five things you need to know in local business news to start your busy Thursday, including World Cup game prices, GSK's latest buy, how Cape Cod got its name and economic experts offer ...

Over the last few days, acquisition suitors of bluebird bio sweetened their offer, RA Capital and Khosla Ventures launched a ...

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...